WAVEMAN · COMPANY

NEOG · Neogen Corp

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

NEOG

Name: NEOGEN CORP (NEOG) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

NEOGEN CORP

PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0000711377

C-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

$4.4K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

152

13F, latest reported quarter

REVENUE GROWTH

-2.7%

XBRL, annual

NET MARGIN

-0.9%

CONVERSIONS · 180D

codes C/M, not in net · $370.3K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$4.4K over 180 days

+$4.4K over 90 days

more than 66% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

152 funds added or opened last quarter

more than 79% of Pharma & Biotech

REVENUE

-2.7% year over year

below 62% of Pharma & Biotech

MARGIN

-0.9% net margin

more than 65% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

4.3% of shares outstanding short · 4.3 days to cover · settled 2026-07-31

more than 50% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

152 funds added or opened positions in the latest 13F quarter, of 320 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +109.8%

+109.8%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $4.4K bought by insiders over 180 days, 152 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, NEOGEN CORP insiders bought a net $4.4K of stock across 49 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Nassif Mikheal

CEO

BUY

2026-08-04

370.0

$4.4K

Nassif Mikheal

CEO

BUY

2026-02-17

23.0

$252

Nassif Mikheal

CEO

BUY

2026-02-02

24.0

$240

Nassif Mikheal

CEO

BUY

2026-01-26

25.0

$246

Nassif Mikheal

CEO

BUY

2026-01-16

137.0

$1.3K

49 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 44 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

33,431,015.0 sh

$300.5M

NEUBERGER BERMAN GROUP LLC

16,570,795.0 sh

$149.0M

VANGUARD PORTFOLIO MANAGEMENT LLC

13,038,732.0 sh

$117.2M

DIMENSIONAL FUND ADVISORS LP

9,828,174.0 sh

$88.4M

VANGUARD CAPITAL MANAGEMENT LLC

9,655,248.0 sh

$86.8M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Clarkston Partners Fund

$9.3M POSITION · AS OF 2026-03-31

3.0%

BARON SMALL CAP FUND

$46.5M POSITION · AS OF 2026-03-31

1.7%

State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF

$2.2M POSITION · AS OF 2026-03-31

1.6%

Small Cap Equity Portfolio

$15.5M POSITION · AS OF 2026-04-30

1.6%

Meridian Contrarian Fund

$9.0M POSITION · AS OF 2026-03-31

1.5%

Invesco S&P SmallCap Health Care ETF

$2.0M POSITION · AS OF 2026-02-28

1.5%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Executive pay vs shareholder return

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2020

$2.5M

$4.6M

$714.9K

+30%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2026-05	2025-05	2024-05	2023-05
REVENUE	$870.4M	$894.7M	$924.2M	$822.4M
GROSS PROFIT	$408.5M	$421.4M	$463.9M	$406.0M
OPERATING INCOME	$-21.6M	$-1.1B	$58.6M	$37.5M
NET INCOME	$-7.9M	$-1.1B	$-9.4M	$-22.9M
EPS (DILUTED)	-0.04	-5.03	-0.04	-0.12
OPERATING CASH FLOW	$83.2M	$58.2M	$35.3M	$41.0M
CASH	$185.5M	$129.0M	$170.6M	$163.2M
LONG-TERM DEBT	$793.7M	$874.8M	$888.4M	$885.4M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE